ICD-10-CM Billable Code

H49.819

Kearns-Sayre syndrome, unspecified eye

Clinical Classification Guidelines

Medical Intelligence & Overview

Kearns-Sayre syndrome is a rare inherited disorder that primarily affects the eye and muscle tissues. It is characterized by progressive weakness and vision problems. Although it can impact other organs, eye problems are usually the most noticeable early symptoms. This condition typically starts in childhood or young adulthood and requires careful management to address the various symptoms. Understanding this syndrome can help patients and their families better cope with its effects and monitor potential health issues.

Causes & Symptoms

Clinical Causes: Kearns-Sayre syndrome is caused by a genetic mutation involving mitochondrial DNA. Mitochondria are the energy-producing structures within cells, and mutations here impair their function. Unlike many genetic disorders, it does not follow a clear inheritance pattern from parent to child. Instead, the mutation usually occurs spontaneously or is inherited maternally (from the mother). The mutation affects multiple tissues that require high energy, including the eyes, muscles, heart, and nervous system, leading to widespread symptoms.

Key Symptoms: Progressive external ophthalmoplegia (weakness or paralysis of the eye muscles), leading to drooping eyelids and difficulty moving the eyes. Retinal pigmentary changes, which can cause vision loss or visual disturbances. Hearing loss, often sensorineural, affecting the ability to hear sounds clearly. Heartbeat irregularities (cardiac conduction defects), which may lead to serious heart complications. Muscle weakness and fatigue, especially in muscles used for movement. Balance and coordination problems due to neurological involvement. Other possible symptoms include diabetes, short stature, and cerebellar ataxia.

Diagnostic & Treatment

Diagnosis Path: Diagnosing Kearns-Sayre syndrome involves a combination of medical history, clinical examination, and specialized tests. Eye examinations will reveal characteristic signs such as ptosis (drooping eyelids) and muscle weakness. Additional procedures include: - Fundoscopy to observe retinal changes. - Electrocardiogram (ECG) to detect cardiac conduction issues. - Blood tests and muscle biopsies to analyze mitochondrial function. - Molecular genetic testing to identify mutations in mitochondrial DNA. Since the syndrome can affect multiple systems, a multidisciplinary approach is often necessary for accurate diagnosis.

Treatment Protocols: While there is no cure for Kearns-Sayre syndrome, various management strategies can help alleviate symptoms and prevent complications: - Regular eye examinations and surgeries for eyelid drooping if necessary. - Hearing aids or cochlear implants to support hearing loss. - Cardiac monitoring to detect and treat heart rhythm disturbances, which may involve pacemaker implantation. - Physical therapy to improve muscle strength and mobility. - Monitoring metabolic health, including blood sugar levels for diabetes management. - Supportive therapies for neurological symptoms as needed. Ongoing care and regular follow-up with a team of specialists can improve quality of life and help manage the syndrome’s progression.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is H49.819 a billable ICD-10 code?
Yes, H49.819 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report H49.819?
Clinical documentation must specify the nature of Kearns-Sayre syndrome, unspecified eye and any associated comorbidities for accurate reporting.

Cite this Clinical Reference